Researchers at the VIB-KU Leuven Center for Brain & Disease Research have uncovered the hidden mechanism behind lecanemab (Leqembi), the FDA-approved Alzheimer's drug. The study, published in Nature Neuroscience and led by Prof. Bart De Strooper, found that the drug clears toxic amyloid plaques by activating the brain's immune cells — microglia — through a specific part of the antibody called the Fc fragment.

Using hybrid mouse models containing human microglial cells, co-first authors Dr. Giulia Albertini and Magdalena Zielonka showed the Fc fragment acts as a trigger that reprograms microglia into an active plaque-clearing state. The team also identified SPP1/osteopontin as a key molecular factor driving effective amyloid removal.

The discovery is significant because it suggests future Alzheimer's therapies could potentially activate microglia directly, bypassing the need for antibodies altogether — a path that could lead to cheaper, more accessible treatments.